Mark Agulnik, MD
Medical Oncology · Los Angeles, CANPI 1164448734
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $188,003 of the $303,006 with a category attached, or 62.0%. 24 manufacturers reported payments, led by Bayer at 28.5% of the total. Reporting peaked in 2019 at $86,441 and has fallen 65.5% since, to $29,811 in 2025. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 318 payments — averaging $952.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$86K
- Deciphera Pharmaceuticals Inc.$85K
- Boehringer Ingelheim$27K
- Regeneron Healthcare Solutions, Inc.$26K
- Daiichi Sankyo Inc.$17K
- Springworks Therapeutics, Inc.$15K
- plus $46K from 18 others
Across 199 payments — averaging $23,681 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Deciphera Pharmaceuticals Inc.$1.1M
- Exelixis Inc.$826K
- Novartis$784K
- Otsuka Pharmaceutical Co., Ltd.$487K
- PTC Therapeutics, Inc.$441K
- Aadi Bioscience, Inc.$257K
- plus $813K from 9 others
What the payments were for
- Consulting fees$86,50329%
- Speaking & faculty fees$188,00362%
- Travel & lodging$20,2947%
- Food & beverage$7,9953%
- Gifts$2120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 75 | $86,255 |
| Deciphera Pharmaceuticals Inc. | 89 | $85,398 |
| Boehringer Ingelheim | 22 | $27,073 |
| Regeneron Healthcare Solutions, Inc. | 24 | $25,692 |
| Daiichi Sankyo Inc. | 27 | $17,492 |
| Springworks Therapeutics, Inc. | 19 | $14,696 |
| E.r. Squibb & Sons, L.L.C. | 10 | $11,872 |
| Aadi Bioscience, Inc. | 17 | $11,466 |
| Sanofi | 8 | $10,547 |
| Blueprint Medicines Corporation | 3 | $5,740 |
| AstraZeneca | 2 | $3,471 |
| Eli Lilly | 1 | $1,050 |
| Lantheus Medical Imaging, Inc. | 1 | $800 |
| Foundation Medicine, Inc. | 2 | $700 |
| Galvanize Therapeutics, Inc | 1 | $198 |
| Tempus AI, Inc | 5 | $137 |
| Exelixis Inc. | 1 | $135 |
| Johnson & Johnson | 3 | $83 |
| Sobi, Inc | 2 | $62 |
| Beone Medicines USA, Inc. | 2 | $41 |
| Astellas Pharma US Inc | 1 | $29 |
| Merck | 1 | $26 |
| Epizyme, Inc. | 1 | $25 |
| Tactile Systems Technology Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vitrakvi$82,839
- QINLOCK$75,476
- LIBTAYO$33,423
- Turalio$16,999
- OGSIVEO$14,454
- OPDIVO$11,612
- FYARRO$11,215
- AYVAKIT$5,740
- VIMSELTINIB$4,569
- LYNPARZA$3,450
- ROMVIMZA$3,351
- Stivarga$2,328
- FOUNDATIONONE LIQUID$700
- FOUNDATIONFOCUS$700
- FOUNDATIONONE CDX$700
- FOUNDATIONONE HEME$700
- FOUNDATIONONE$700
- ALIYA SYSTEM$198
- Cabometyx$135
- TGCT$117
How this compares
$303,006 in reported general payments places this provider in the 90th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 55 | $58,267 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Los Angeles
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
- Heinz-Josef LenzLos Angeles$185K
- Syma IqbalLos Angeles$178K
- Anthony El-KhoueiryLos Angeles$156K
- David QuinnLos Angeles$134K
- David TranLos Angeles$128K
- Afsaneh BarziLos Angeles$107K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.